Open an account

Medicine Man Technologies

SHWZ · OTC

$0.00+$0.00 (+900.00%)TodayMarket closed ·
No price history for this range.

About SHWZ

Medicine Man Technologies, Inc. engages in the cultivation, manufacture, distribution, and retail sale of cannabis and cannabis related products. The company is headquartered in Denver, Colorado and currently employs 729 full-time employees. The company went IPO on 2015-12-23. The Company’s business involves the cultivation, manufacturing, distribution and retail sale of cannabis and cannabis-related products. The firm sells products it manufactures and cultivates and a variety of other cannabis goods through wholly owned retail stores, licensing arrangements, and/or third-party operators and retailers. The company has three segments: Retail, Wholesale and Other. The Retail segment consists of retail locations for the sale of cannabis products. The Wholesale segment consists of manufacturing, cultivation and sale of both wholesale cannabis and non-cannabis products. The Other segment encompasses the Company’s general corporate operations, in-store advertisements, and certain vendor promotions. The firm owns and operates approximately 63 retail dispensaries.

Employees
729
Headquarters
Denver, Colorado
Listed
Dec 23, 2015
Sector
Health Care
Industry
Pharmaceuticals
Website
medicinemantechnologies.com

SHWZ key statistics

Market cap
865
Price-earnings ratio
-0.00
Dividend yield
—
Average volume
70.95K
Volume
588.80K
Open price
$0.00
High today
$0.00
Low today
$0.00
52 Week high
$0.0099
52 Week low
$0.00

Medicine Man Technologies (SHWZ) at a glance

As of Sep 29, 2026, Medicine Man Technologies (SHWZ) shares are priced at $0.00, giving the company a market cap of 865 and a price-to-earnings ratio of 0.00.

Volume so far is 588.80K shares, above the average of 70.95K shares a day.

Over the past year Medicine Man Technologies has ranged from $0.00 to $0.0099, and now sits 0% of the way up that range.

Medicine Man Technologies met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY24 it reported -$0.20 per share against an estimate of -$0.1938.

SHWZ earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 85.3% on average.

  1. Q3 FY22: reported $0.00 per share against an estimate of -$0.0204
  2. Q4 FY22: reported -$0.30 per share against an estimate of -$0.0136
  3. Q1 FY23: reported -$0.06 per share against an estimate of -$0.0408
  4. Q2 FY23: reported -$0.15 per share against an estimate of -$0.0612
  5. Q3 FY23: reported -$0.03 per share against an estimate of -$0.102
  6. Q4 FY23: reported -$0.43 per share against an estimate of -$0.1326
  7. Q1 FY24: reported -$0.24 per share against an estimate of -$0.1632
  8. Q2 FY24: reported -$0.20 per share against an estimate of -$0.1938

SHWZ news

  • Press releaseGlobe Newswire

    Schwazze Reaches Agreement to Restructure its Balance Sheet and Portfolio of Assets

  • Nicolás Jose Rodriguez

    Why Cannabis Sales Are Down In Massachusetts And New Mexico: The Numbers Behind The Dip

  • Nicolás Jose Rodriguez

    Ka-Ching! Schwazze's Cannabis Accounting Bloopers And Other Historic Missteps That Shook Up Big Business

  • Nina Zdinjak

    Schwazze's Q3 Preliminary Revenue Slides As Debt Grows, 2023 Financials Face Re-Audit

  • Nicolás Jose Rodriguez

    Is Colorado's Cannabis Market Back On Track? A 5% Sales Boost Says Yes

  • Rolando García

    Almost Every Major Cannabis Company Could See Positive Cash Flow If 280E Is Removed In 2025

  • Nicolás Jose Rodriguez

    Don't Let Hidden Debt Fool You: How Cannabis Investors Can Tell If They Are Safe

  • Jelena Martinovic

    Cannabis Companies About To Release Earnings Reports, Get Your News Here: Glass House, Schwazze And More

Similar companies

Companies in the same industry as Medicine Man Technologies

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.